Menu

Citicoline

Also known as: CDP-choline, Cytidine diphosphate choline

A distinct choline-containing compound with a limited memory signal, not an established general cognition or stroke treatment.

Gouache study of white powder in a ceramic bowl beside an amber vial
Editorial illustration

Citicoline, or CDP-choline, is a choline-containing compound used in supplements and studied in neurological settings. A small older-adult trial found improvement on some memory measures, but EFSA's 2024 assessment did not establish the proposed memory-support claim. The large ICTUS trial also found no recovery benefit in its acute-stroke population. These are different questions, not interchangeable results.1, 2, 4

  • The 2021 memory trial enrolled 100 adults aged 50–85 with age-associated memory impairment.1
  • Its primary Spatial Span outcome did not show a significant between-group benefit.1, 2
  • The 2,298-patient ICTUS trial found no improvement in its global stroke-recovery outcome.4

What is Citicoline?

Citicoline is not plain choline or alpha-GPC. The 2013 EFSA safety opinion evaluated a specified high-purity ingredient and proposed adult uses. That safety conclusion does not approve a memory claim or establish the safety of arbitrary doses and combinations.3

Where it comes from

Natural sources

  • CDP-choline participates in human phospholipid metabolism

How it's made

Supplement-grade citicoline is manufactured to defined specifications; it is not interchangeable milligram-for-milligram with other choline compounds.

What it does in products

  • Ingredient in cognition-marketed supplements
  • Compound studied in separate neurological drug trials

Benefits

Memory performance in selected older adults

limited evidence

One trial found an episodic-memory signal, but the broader proposed memory-support claim remains unestablished.1, 2

The 12-week trial used 500 mg/day in adults with age-associated memory impairment. Secondary episodic and composite scores improved; the primary working-memory measure did not. Manufacturer-affiliated authors and inconsistent wider findings limit generalization.

Evidence scope and limitations

Oral citicoline in selected older-adult memory studies, EFSA's specified-ingredient assessments and the separate ICTUS acute-stroke trial; not all neurological indications.

  • One secondary memory signal is not a consistent general cognition benefit.
  • Manufacturer affiliation and a short follow-up limit the 2021 trial's interpretation.
  • Healthy older-adult findings cannot establish treatment of dementia or other neurological disease.
  • European assessments do not determine U.S. drug authorization or individual suitability.

Evidence last checked: 2026-10-09

Side effects & safety

Headache and incomplete longer-term safety information (varies)One memory-trial participant withdrew with a possibly product-related headache. Short-term tolerability cannot exclude uncommon events or establish safety in unstudied populations.

Safety considerations

  • The cited proposed-use assessment and older-adult trial do not establish safety in pregnancy, breastfeeding or children.
  • The memory trial excluded major diseases and medicines affecting cognition. It does not clear use alongside prescribed neurological treatment.
  • Not for: New or worsening cognitive symptoms need clinical assessment rather than assuming a supplement addresses the cause.
  • Not for: Citicoline supplements are not a substitute for urgent stroke evaluation and established care.
1, 2, 3

Amounts studied & product use

These figures describe research or common product use, not a personal dose or treatment recommendation.

In supplement studies and products

The memory trial used 500 mg/day for 12 weeks. EFSA's 2013 opinion assessed a specified ingredient for proposed adult supplement use up to 500 mg/day. ICTUS used a separate hospital regimen of 1,000 mg every 12 hours, initially intravenous then oral. None is a personal dosing recommendation.

1, 3, 4

Regulatory status

  • U.S. supplement marketing is not FDA approval of a memory or stroke treatment. EFSA's European safety opinion and health-claim evaluation answer separate questions and do not establish U.S. drug approval.
5, 3, 2

The result depends on which question was asked

The memory trial's positive secondary results should be read alongside its nonsignificant primary outcome and EFSA's wider assessment. The manufacturer-affiliated trial does not, by itself, settle a general cognition claim.

ICTUS studied moderate-to-severe acute ischemic stroke, not healthy people shopping for memory support. Its null result matters for stroke claims, while neither trial establishes that retail supplementation prevents dementia.

1, 2, 4

Frequently asked questions

Does a safety opinion prove a memory benefit?

No. The 2013 safety assessment and 2024 health-claim assessment addressed different endpoints; the later assessment did not establish the proposed memory claim.3, 2

Can the stroke trial be treated as a supplement dose guide?

No. ICTUS used a medically supervised acute-stroke regimen with an initial intravenous route, and did not improve global recovery. It is not an OTC dosing template.4

The bottom line

Keep the limited memory signal, a defined ingredient's safety assessment and the negative acute-stroke trial attached to their actual populations and endpoints.

References

  1. Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F. Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. The Journal of Nutrition (2021) · randomized trial · PMID 33978188; DOI 10.1093/jn/nxab119
  2. EFSA Panel on Nutrition, Novel Foods and Food Allergens. ‘Citicoline’ and support of the memory function: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal (2024) · government guidance · DOI 10.2903/j.efsa.2024.8861
  3. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the safety of ‘citicoline’ as a Novel Food ingredient. EFSA Journal (2013) · safety assessment · DOI 10.2903/j.efsa.2013.3421
  4. Dávalos A, Alvarez-Sabín J, Castillo J, et al.. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). The Lancet (2012) · randomized trial · PMID 22691567; DOI 10.1016/S0140-6736(12)60813-7; NCT00331890
  5. Dietary Supplements. U.S. Food and Drug Administration · government guidance · Undated resource; accessed October 9, 2026

Revision history

  1. Initial AI-assisted source checks and claim-level citation mapping under the site-authorized publishing workflow. No separate human or independent medical review is claimed.